GE Healthcare has announced the introduction of SenoBright Contrast Enhanced Spectral Mammography (CESM) technology. CESM uses images acquired at different X-ray energy levels to identify breast tumors. One image is obtained in the conventional mammography range of 26 to 32 kilovolt peak (kVp), providing morphological information, and one using voltages in the 45 to 49 kVp range, capturing the diffusion of a contrast agent within the breast. These images are then combined into one using proprietary algorithms. The resulting image highlights angiogenesis, which is associated with tumor growth. SensoBright brings the sensitivity and specificity of mammography closer to that of MRI, while keeping the examination time short. It does however add the need to inject a contrast agent before the exam. The technology is implemented as an upgrade to GE Healthcares Senographe DS and Senographe Essential digital mammography systems, but radiologists willing to use it might have to wait a little longer, as it has not yet received CE or FDA approval.